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Optimal composition of intravenous lipids
The composition of an intravenous (IV) lipid emulsion is of great 
importance in parenteral nutrition (PN) therapy, as most of its effects 
depend on the kind of fatty acids included and their respective ratio 
to each other. Today´s lipid emulsions may include four classes of 
different fatty acids (FA), namely ω−6 long chain polyunsaturated 
fatty acids, ω−3 long chain polyunsaturated fatty acids, ω−9 long 
chain monounsaturated fatty acids and medium chain saturated 
fatty acids. All these fatty acids present a source of energy with a 
low osmolarity but they strongly differ in their immunologic effects 
and their effects on oxidative stress, liver injury and mitochondrial 
function. For this review the effects of the different admixtures will 
be discussed following the time line of their landmark introduction 
into clinical practice. 
The first lipid emulsion for parenteral application was a 100% soy 
bean oil-based emulsion introduced in 1961. There were two reasons 
for the development of this type of lipid emulsion. Firstly, soy bean oil 
contains the two essential ω–6 fatty acids, linoleic acid and linolenic 
acids, and secondly, soy bean oil was readily available. Very soon after 
its introduction into clinical practice its immunologic properties came 
into discussion1 and with its widespread use  concerns were raised 
regarding  its  immune-compromising effects and the increased risk 
of infections.2,3 Today, there is consistent evidence from human and 
animal in vitro and ex vivo studies showing that ω–6 fatty acids 
or a soy bean oil-based emulsion inhibit lymphocyte proliferation,4,5 
decrease natural and lymphokine activated killer cell acitivity,6,7 
decrease chemotaxis and random migration of granulocytes8–10 and 
negatively affect the reticuloendothelial system.11,12
Despite these impressive experimental results, some smaller trials in 
malnourished or paediatric patients13–15 and one large clinical trial in 
bone marrow transplanted patients16 found no significant difference 
between patients who received a parenteral ω–6 emulsion  and 
those who did not. One smaller crossover study even reported an 
immunorestorative effect of the lipid emulsion.17 In contrast, the 
study reported by Battistella18 randomised 60 trauma patients with 
a severity score of 27 and an APACHE II score of 23 to 10 days of 
postoperative PN with our without an ω–6 emulsion. Patients who 
received the lipid emulsion had a longer length of hospitalisation 
(39 vs 27 days), a longer length of stay in the intensive care unit 
(29 vs 18 days) and more days of mechanical ventilation (27 vs 15) 
(Figure 1) The group which received the lipid emulsion also had a 
significantly reduced natural and lymphokine activated killer cell 
activity and a higher number of infections (72 vs 39). Although this 
trial is somewhat biased by the fact that the group which did not 
receive the  lipid emulsion also received 25% less energy, these 
negative results made the Canadian, the European and also the 
American guideline committee recommend that – at least – intensive 
care patients should not receive pure ω–6 lipid emulsions as part of 
their PN regimens.
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Figure 1: Battistella FD et al. Lipid emulsion in trauma victims
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In order to reduce the amount of ω–6 fatty acids in a lipid emulsion, 
medium chain triglycerides were introduced into clinical practice in 
1984. These fatty acids with a chain length of 8 resp. 10 carbon 
atoms are derived from coconut oil. In vitro and ex vivo studies could 
show that a 50/50 admixture of ω–6 FA and MCT (ω–6/MCT) could 
prevent the inhibition of lymphocyte proliferation,19 that natural killer 
cell activity was less reduced,20 and that the expression of adhesion 
molecules 21,22 as well as the phagocytic capacity of the RES 
were increased.23,24 On the other hand it was also shown that the 
phagocytic capacity for C. albicans was significantly reduced.25,26 
Seven smaller trials19,27–32  in patients with ARDS, acquired immune 
deficiency syndrome, sepsis or undefined critically ill patients showed 
no significant difference in any important outcome parameter. One 
of two medium size trials (n = 72) showed less intra-abdominal 
infections and a trend towards reduced mortality in malnourished 
surgical patients33 and the other one a significantly greater rise in 
retinol binding protein and nitrogen balance in septic patients.34 
However, as there are no harmful results, ω–6/MCT lipid emulsions 
are still in use and may still be used in critically ill patients.
The next step in the development of intravenous lipid emulsions was 
a further reduction in the ω−6 FA content to 20% and the completion 
with ω−9 oleic acid from olive oil (OO) – which was introduced in 
1996. The concern with this new emulsion was that the low content 
of ω−6 FA might lead to a deficiency in essential FAs. This concern 
was partly addressed  by a study in children reported by Munck35 
which documented that such a lipid emulsion could reduce the 
C20:3 content – a sign of essential acid deficiency – over 15 days 
as well as ω−6 FA. There are also experimental studies that showed 
that ω−9 FA or a lipid emulsion based on ω−9 FA (ω−9/ω−6) did not 
inhibit lymphocyte proliferation,35,36 did  not reduce the expression 
of activation markers on granulocytes21,35,37 and that it had almost 
no effect on the release of proinflammatory cytokines.38–41 Thus, its 
effect on most immunologic parameters was almost neutral.
This ω−9/ω−6 emulsion was evaluated in six trials in preterm 
infants42–48 and in three trials in paediatric patients.35,49–51  All trials 
showed a good short and (some studies) long term tolerability 
and no signs of essential fatty acid deficiency. In adults, this ω−9/
ω−6 emulsion was administered over three to six months in home 
parenteral nutrition.52–54 Besides seven mostly smaller trials in various 
patients, this emulsion was also studied in one observational55 and 
two controlled trials56,57 in critically ill patients. The trial reported by 
Huschak57 randomised 33 severe multiple trauma patients to either 
high dose ω−9/ω−6 (75% of non-protein energy) or normal dose 
ω−6 FA (37% of non-protein energy). They found a significant shorter 
length of ventilation and a significantly shorter length of stay in the 
ICU in the high dose ω−9/ω−6 group (Figure 2). The trial reported 
by Garcia-de-Lorenzo56 also found significantly less abnormalities in 
liver function in the ω−9/ω−6 group.
The next lipid emulsion – introduced in 1991 – was based on ω−3 
fatty acids derived from fish oil (FO). In many in vitro and ex vivo 
studies it could be shown that ω−3 fatty acids had strong anti-
inflammatory and immunosuppressive effects, already documented 
in various diseases such as rheumatoid arthritis, inflammatory 
bowel disease and asthma. Thus lipid emulsion inhibited lymphocyte 
proliferation,58–61 decreased natural killer cell activity6,62 as well 
as monocyte chemiluminescence, chemotaxis and adhesion to 
endothelial cells63–65 and it reduced the release of proinflammatory 
cytokines.66–68 
As the ω−3 fatty acids emulsion (ω–3) was never licensed for a 
standalone use but had to be administered in addition to another 
lipid emulsion, there are only few experimental clinical studies on 
the use of pure ω−3.69–71 In these, its main effect was to modulate 
cytokine and leukotriene release (Figure 3).
As far as the admixture of ω−3 to other lipids is concerned, an 
important experiment was performed by Grimm et al72 in 1994. They 
performed allogenic heart transplantations in inbred rats and fed 
them postoperatively with different lipid emulsions: fish oil, soybean 
oil, safflower oil or a mixture of safflower with fish oil with a ratio of 
2.1:1. The rejection time of the allograft was significantly prolonged 
with fish oil but also with safflower or soybean oil. However, the 
mixture of safflower with fish oil induced a rejection time which was 
comparable to control animals (Figure 4). This experiment was the 
base for the ω−6:ω−3 ratio in the supplemental use of ω−3 with 
ω−6 and also for all lipid emulsions containing fish oil which were 
introduced after 2005.
It might be concluded from these data that an admixture with the 
described ω−6:ω−3 ratio is mostly immune-neutral. However, 
experimental data on the immunologic effect of these latest lipid 
emulsions are very rare. De Nardi et al73 found yet a significant 
increase in macrophages that had engaged in phagocytosis with 
ω−6/MCT and ω−6/MCT/FO. However, there was no increase with 
ω−6/MCT/FO/OO.
There are many clinical studies concerning the addition of fish oil to 
lipid emulsions. They can be divided into studies using the admixture 
of pure ω−3 to other lipids, studies using ω−6/MCT/FO, or studies 
using ω−6/MCT/FO/OO.
Figure 2 : Huschak G et al.57 Olive oil based nutrition in multiple trauma 
patients
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There are two observational74,75 and nine randomised controlled76–83 
trials on the admixture of pure ω−3 FA to other lipids. While none of 
the randomised trials showed a significant improvement in survival 
or length of stay, the observational trial reported by Heller et al74 
showed that FO had the most favorable effects on survival, infection 
rates and length of stay when administered in doses between 0.1 
and 0.2 g/kg/day. 
The eight studies which evaluated ω−6/MCT/FO84–91 also didn’t 
show any significant effect on outcome except the trial reported by 
Wichmann et al87 which showed a significant decrease in the length 
of stay (17.2 vs 21.9 days). 
Of the three studies evaluating ω−6/MCT/FO/OO,92–94 the study 
reported by Mertes et al93 showed a trend towards a reduced length 
of hospital stay (15.7 +/- 6.3 vs 17.8 +/- 13.2 days). Piper et al92 
compared ω−6/MCT/FO/OO to ω−9/ω−6 and found at day two and 
five significantly lower levels of liver enzymes in the ω−6/MCT/
FO/OO group. However, the importance of this result is limited by 
the fact that the higher levels found with ω−9/ω−6 also were only 
slightly above normal range.
In conclusion, ω−9/ω−6 with its relative immune-neutrality is a lipid 
emulsion that can be used in most critically ill and non-critically ill 
patients. The addition of fish oil in the newer ω−6/MCT/FO or ω−6/
MCT/FO/OO emulsions certainly has advantages compared to pure 
ω−6 or ω−6/MCT and these emulsions can also be used in most 
patients. However, the drawback is that the immune-modulatory 
potential of these emulsions is rather low as the fish oil content is too 
low to exert a greater effect. So there is still need for a lipid emulsion 
that could be advantageous in patients with real hyperinflammation. 
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